Connect Biopharma Reports Q2 2026 Financial Results

What Happened
Connect Biopharma Holdings Limited filed a Form 8‑K on August 12, 2026 to announce its financial results for the three and six months ended June 30, 2026. The company issued a press release with those results, which is attached to the 8‑K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: August 12, 2026 (Form 8‑K, Item 2.02: Results of operations and financial condition).
• Reporting periods: three-month and six-month periods ended June 30, 2026.
• Press release containing the earnings/quarterly results is attached as Exhibit 99.1 to the filing.
• Form 8‑K was signed by Lisa Peraza, Senior Vice President, Finance.

Why It Matters
This 8‑K notifies investors that Connect Biopharma has released its quarterly earnings and related financial information (revenue, net results, cash position and other metrics will be in the attached press release). Investors should review Exhibit 99.1 for the specific revenue and earnings figures and any management commentary, since those numbers can affect valuation and near‑term stock performance.